[Castration resistant prostate cancer 2015]. / Kastrationsresistentes Prostatakarzinom 2015.
Aktuelle Urol
; 46(1): 59-65, 2015 Jan.
Article
em De
| MEDLINE
| ID: mdl-25658232
ABSTRACT
Prostate cancer is still the most common urological cancer of the elderly man. In some patients, a metastatic prostate cancer arises which may remain a stable disease for years with palliative antiandrogen therapy. On average, after 3-4 years, affected men develop a PSA rise and disease progression with the formation of a so-called castration-resistant disease. 5 years ago cytotoxic chemotherapy with docetaxel was the only life-prolonging treatment option in this situation. In the last 5 years, the results of randomised phase III studies have led to the approval of 5 new agents for the treatment of metastatic castration resistant prostate cancer (mCRPC). The results and approval status of the substances, Abiraterone, Enzalutamide, Cabazitaxel, Sipuleucel-T and radium-223 are described below. In addition, some aspects of sequential therapy and possible future molecular approaches are discussed.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Rádio (Elemento)
/
Neoplasias de Próstata Resistentes à Castração
/
Antineoplásicos
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Humans
/
Male
Idioma:
De
Revista:
Aktuelle Urol
Ano de publicação:
2015
Tipo de documento:
Article